Gordon B. Mills, MD, PhD

Gordon B. Mills, MD, PhD, chair of Systems Biology, co-director of the Institute of Personalized Medicine, University of Texas MD Anderson Cancer Center, discusses the oncological trend of moving toward individually treating patients with breast cancer. Mills says this individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.

Videos

&#8203;Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.

Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer

Mills says there is an incredible amount of new information arising from the cancer genome atlas, as well as similar programs in the academic community. Thus far, information has mostly focused on the DNA and RNA levels so far. Mills and his colleagues are investigating a protein-based analysis of the cancer genome.

This provides new information and opportunities that were not previously present, says Mills.

Gordon B. Mills, MD, PhD, professor of medicine and immunology, Olga Keith Wiess Distinguished University Chair for Cancer Research, co-director, Zayed Institute for Personalized Cancer Therapy, chair, Department of Systems Biology, Ann Rife Cox Chair in Gynecology, administrative director, Kleberg Center for Molecular Markers, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.

Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.


Gordon B. Mills, MD, PhD | Authors

Articles

Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer

Dr. Mills Discusses Assay of the Genome to Further Measure DNA and RNA